Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.52 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323036 | 0.89 | DYRK1A (0.56) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL10324008 | 0.84 | DYRK1A (0.47) | CSNK2A1DYRK1ALCKMAPK14 | |
| SCHEMBL10323705 | 0.83 | DHODH (0.45) | — | |
| SCHEMBL10323489 | 0.82 | DYRK1A (0.55) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL10324022 | 0.80 | HSP90AA1 (0.42) | — | |
| SCHEMBL4074395 | 0.79 | FGFR1 (0.52) | MERTKTYRO3GAS6CSNK2A1FGFR1 | |
| SCHEMBL4763435 | 0.79 | GAA (0.49) | MERTKTYRO3GAS6GAA | |
| SCHEMBL34462305 | 0.76 | MERTK (0.81) | MERTKTYRO3GAS6 | |
| SCHEMBL10322497 | 0.75 | POLB (0.50) | DYRK1A | |
| SCHEMBL10446966 | 0.75 | DYRK1A (0.64) | FGFR1FGFR2FGFR4FGFR3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | MERTK 1165/4885TYRO3 1781/4885GAS6 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.